Scientists whose mission is to make people feel better – in this case, those who bear the life sentence called diabetes – offered favorable news Wednesday.
That’s when London, Ontario-based Sernova Corp. (TSX-Venture:SVA) announced that, in an interim analysis of its human Phase I/II clinical trial, Sernova's Cell Pouch transplanted with islet cells showed initial safety, as well as key efficacy measures, including glucose-stimulated C-peptide, insulin production and additional clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness.
Preliminary data was presented Wednesday at the 17th World Congress of the International Pancreas and Islet Transplantation Association in Lyon, France.
Highlights of the presentation of the data from the first patient who received islet transplanted into Sernova Cell Pouch included no incidences of adverse events determined to be related to the Cell Pouch implant.
Wednesday’s news release also mentioned that the Cell Pouch was well-incorporated with vascularized tissue, which enabled successful transplant of the purified islets.
Sernova shares acquired a penny, or 4.2%, soon after noon ET on Wednesday, to 25 cents, on volume of more than 425,000 shares
